FCGR2A and cancer: Taken together, our integrative strategy revealed ITGA2B, FLNA, GRB2, FCGR2A, and APP as high-confidence, FDA-targetable candidates that intersect cancer-associated platelet education with pro-metastatic platelet signaling.